Document |
Document Title |
WO/2010/132982A1 |
It is reported herein that certain muscle diseases and conditions, including forms of muscular dystrophy, are characterized by impaired insulin-dependent signaling in the muscle tissue, in essence, a form of insulin resistance. The prese...
|
WO/2010/127991A1 |
The present invention relates to a method for preparing fluoroalkanesulphinic acid esters. The invention specifically relates to the preparation of esters of trifluoromethanesulphinic acid, commonly referred to as "triflinic acid". The m...
|
WO/2010/104177A1 |
A fluoroalkanesulfinic acid ammonium salt is obtained using an organic base when a bromofluoroalkyl carboxylate ester is sulfinated using a sulfinating agent. The fluoroalkanesulfinic acid ammonium salt is oxidized, thereby obtaining a f...
|
WO/2010/104178A1 |
An ammonium hydroxyfluoroalkanesulfinate is obtained by using an organic base while sulfinating a bromofluoroalcohol with a sulfinating agent. An ammonium hydroxyfluoroalkanesulfonate is obtained by oxidizing said ammonium hydroxyfluoroa...
|
WO/2010/100337A1 |
The present invention relates to novel prodrugs of metformin, their pharmaceutically acceptable salts, pharmaceutical compositions containing the prodrugs, and methods of using the prodrugs. In particular, the present invention relates t...
|
WO/2010/096677A2 |
Compounds are provided that comprise dinitroso-derivatives of dihydrolipoic acid. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating various diseases and disorders, including angina, hype...
|
WO/2010/050392A1 |
An aimed alkoxycarbonylfluoroalkanesulfonic acid salt is obtained by using a halofluoroalkanoic acid ester as a starting raw material, and by sulfinating the ester in the presence of an amine (step 1) and then oxidizing the resulting pro...
|
WO/2010/037693A1 |
The invention relates to a method for purifying trifluoromethanesulfinic acid by azeotropic distillation using an aromatic solvent, to a method for producing purified trifluoromethanesulfinic acid, and to the use of the purified trifluor...
|
WO/2010/013687A1 |
A perfluoroalkanesulfonyl halide is reacted with hydrazine to obtain a perfluoroalkanesulfinic acid hydrazine salt (RfSO2H·N2H4). The hydrazine salt obtained is reacted with a base such as an alkali metal hydroxide to obtain a perfluor...
|
WO/2009/133052A1 |
The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptab...
|
WO/2009/128907A1 |
Processes useful for making a pharmaceutically useful compound according to Formula (I), forms of such a compound, and intermediates useful in such processes are described.
|
WO/2009/099902A1 |
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...
|
WO/2009/068533A1 |
The present invention relates to a method for preparing a highly pure trifluoromethanesulphinic acid. The method of the invention for preparing a highly pure trifluoromethanesulphinic acid, starting from an aqueous mixture comprising a t...
|
WO/2009/068534A1 |
The present invention relates to a method for preparing a salt of trifluoromethanesulphinic acid termed "triflinic acid". More specifically, the invention relates to a method for preparing a highly pure triflinic acid salt. The method of...
|
WO/2009/009041A2 |
The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
|
WO/2008/110698A2 |
The invention relates to a method for preparing polyfluorinated sulphanylamides of formula (I) and polyfluorinated sulphinamidines of formula (II), wherein R1-R4 are defined as in the claims, and for preparing the precursors of same.
|
WO/2008/038640A1 |
Disclosed is a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid. Also disclosed is a method for producing a salt of trans-4-sulfinylamino-1-cyclohexanecarboxylic acid.
|
WO/2008/009816A2 |
The invention relates to aromatic sulfinates and sulfonyl halides, and to the preparation thereof. The halides and the sulfinates are respectively of formulae Ar-Z- (CF2) n-CFRf-SO2Y (I) and [Ar-Z- (CF2) n-CFRf-SO2] m M wherein Z is a su...
|
WO/2007/128893A1 |
The present invention concerns an improved method for preparing oxysulfide and fluorinated organic derivatives. The invention relates to the preparation of perfluoroalkanesulfinic and sulfonic acids, and preferentially trifluoromethanesu...
|
WO/2007/107311A2 |
The invention relates to special sulphinic acid derivatives of formula (I), wherein M represents a hydrogen atom or an equivalent of a monovalent or polyvalent cation, R is derived from a peptide or represents a group according to one of...
|
WO/2006/106800A1 |
Disclosed is a method for producing a compound (III), a salt thereof or a solvate of them by reacting a compound (I), a salt thereof or a solvate of them with a compound (II) in a toluene solvent in the presence of an additive such as wa...
|
WO/2006/059252A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring ...
|
WO/2006/050471A2 |
Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereo...
|
WO/2006/030208A1 |
The present invention relates to enantiopure, non-proteinogenic &agr -amino acids, and methods for the synthesis thereof, that are useful as, or in the synthesis of, pharmaceutical, nutraceutical or agricultural products.
|
WO/2005/067502A2 |
Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including al...
|
WO/2005/063018A1 |
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...
|
WO/2005/035591A1 |
Compositions are provided that include an electron donor and a sensitizing compound. More specifically, the electron donor is an arylsulfinate salt. Methods of polymerization are also provided that can be used to prepare polymeric materi...
|
WO/2005/035590A1 |
Compositions are provided that that can be used as an initiator system for free radical polymerization reactions. More specifically, the initiator systems include an electron acceptor and an electron donor. The electron donors are arylsu...
|
WO/2005/034885A1 |
Compositions are provided that include a photoinitiator system for free radical polymerization reactions. More specifically, the photoinitiator includes an arylsulfinate ion and a triarylsulfonium ion. Polymerization methods are also pro...
|
WO/2004/072087A2 |
The invention relates to novel metal complexes for optical data carriers, whereby the latter is preferably a transparent substrate which is, optionally already covered with one or several reflective layers. A light-inscriptible informati...
|
WO/2004/026814A2 |
The invention is a process for the preparation of compounds of the Formula (I): where R1, R2, R3, R4 and R5 are defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors useful in the treatmen...
|
WO/2004/024130A2 |
Treatment of central nervous system disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthal
enamine and with (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthal
enamine is disclose...
|
WO/2004/018414A2 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
|
WO/2004/002950A1 |
A sulfenyl compound represented by the general formula R-S-X (1) (wherein R represents an organic group having at least one constituent element labeled with an isotope; and X represents a leaving group); a labeling reagent containing the...
|
WO/2004/000856A1 |
The present invention relates to a medicament comprising, separately or together, (i) at least one reflux inhibitor; and (ii) at least one imidazopyridine. A further aspect of the invention relates to methods of treatment of gastro-esoph...
|
WO/2004/000855A1 |
The present invention relates to a medicament comprising, separately or together, (i) at least one acid secretion inhibiting agent; and (ii) at least one reflux inhibitor. A further aspect of the invention relates to methods of treatment...
|
WO/2003/106407A1 |
A process for the production of fluorine-containing fluorosulfonylalkyl vinyl ethers represented by the general formula: CF2=CFO(CF2CF(CF3)O)nCF2(CF2CF2)mCF2SO2F (wherein m is an integer of 0 to 5 and n is an integer of 0 to 10), charact...
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
WO/2003/091207A2 |
This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfmyl group a residue of an alcohol, thiol or amine, or reacting a sulfmylimine stereoisome...
|
WO/2003/086282A2 |
The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one...
|
WO/2003/076374A1 |
A process for producing a compound (I) which comprises the step of reacting a compound (II) with a base in an aprotic solvent as shown by the scheme: (II) (I) wherein R1 and R2 each independently represents lower alkyl.
|
WO/2003/059873A1 |
This invention relates to novel compounds characterized by the general Formula (I) any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, or an N-oxide thereof, useful as potassium channe...
|
WO2002039965B1 |
The invention relates to a reducing composition for the permanent deformation of the hair comprising an N-substituted formamidinesulphinic acid derivative as reducing agent and to a process for the permanent deformation of the hair emplo...
|
WO/2003/050066A1 |
This invention is directed to functionalized higher diamondoids having at least one functional group. These derivatives have a higher diamondoid nucleus and up to six independently selected functional groups. The functionalized higher di...
|
WO/2003/032908A2 |
The present invention relates to novel prodrugs of pharmaceutical compounds containing one or more N-H bonds. More specifically, the present embodiment of the invention relates to prodrugs wherein sulfur-containing promoieties are attach...
|
WO/2003/011844A2 |
The invention concerns a composition for perfluoroalkylation of an electrophilic substrate. Said composition comprises for successive or simultaneous addition: a) at least one of the compounds of formula (I) Rf-Z(O)¿n?-Y, wherein: Z rep...
|
WO/2003/004091A2 |
The present invention discloses novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-inf...
|
WO/2002/102250A1 |
A positron emission tomography (PET)-ready library of candidate pharmaceutical agents is provided which can be prepared by a multistep process wherein the final or penultimate step is a reaction using a PET-ready reagent or a plurality o...
|
WO/2002/100823A1 |
Novel compounds of formula (I) wherein R¿1? represents hydrogen; R¿2? represents hydroxy, fluoro or an oxo group;R¿3? represents hydrogen; R¿4? represents hydrogen; and pharmaceutically acceptable salts, solvates and the stereoisomer...
|
WO/2002/096516A1 |
A method is provided for the prevention or inhibition of cardiovascular disease comprising the admiministration of a cyclooxygenase-2 selective inhibitor with a dose of radiation.
|